We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Citigroup (C) Beats on Q2 Earnings & Revenue Estimates
Read MoreHide Full Article
Have you been eager to see how Citigroup (C - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based money center bank’s earnings release this morning:
An Earnings Beat
Citigroup came out with adjusted earnings per share of $1.62, surpassing the Zacks Consensus Estimate of $1.54. Further, the figure compared favorably with earnings of $1.28 in the prior-year quarter. Improvement in earnings was primarily driven by higher revenues and expense management.
How Was the Estimate Revision Trend?
You should note that the earnings estimate for Citigroup depicted pessimism prior to the earnings release. The Zacks Consensus Estimate was revised downward slightly over the last seven days.
Also, Citigroup has a decent earnings surprise history. Before posting earnings beat in Q2, the company also delivered positive surprises in the prior four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 6.11% in the trailing four quarters.
Citigroup’s revenues of $18.5 billion surpassed the Zacks Consensus Estimate of $18.4 billion. Moreover, revenues increased 2% year over year.
Key Takeaways
Net Income stood at $4.5 billion, up 16% from the prior year quarter.
Costs of credit surged 6% year over year to $1.8 billion.
Fixed income markets revenues declined 6% year over year to $3.1 billion
Equity markets revenues of $864 million surged 19% from the prior-year quarter.
Returned $3.1 billion to shareholders as common stock repurchases and dividends during the quarter.
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Citigroup. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Following the earnings release, Citigroup shares were down more than 1% in the pre-trading session. This is in contrary to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have not considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this Citigroup earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Citigroup (C) Beats on Q2 Earnings & Revenue Estimates
Have you been eager to see how Citigroup (C - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based money center bank’s earnings release this morning:
An Earnings Beat
Citigroup came out with adjusted earnings per share of $1.62, surpassing the Zacks Consensus Estimate of $1.54. Further, the figure compared favorably with earnings of $1.28 in the prior-year quarter. Improvement in earnings was primarily driven by higher revenues and expense management.
How Was the Estimate Revision Trend?
You should note that the earnings estimate for Citigroup depicted pessimism prior to the earnings release. The Zacks Consensus Estimate was revised downward slightly over the last seven days.
Also, Citigroup has a decent earnings surprise history. Before posting earnings beat in Q2, the company also delivered positive surprises in the prior four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 6.11% in the trailing four quarters.
Citigroup Inc. Price and EPS Surprise
Citigroup Inc. Price and EPS Surprise | Citigroup Inc. Quote
Revenue Came In Higher than Expected
Citigroup’s revenues of $18.5 billion surpassed the Zacks Consensus Estimate of $18.4 billion. Moreover, revenues increased 2% year over year.
Key Takeaways
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Citigroup. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
How the Market Reacted So Far
Following the earnings release, Citigroup shares were down more than 1% in the pre-trading session. This is in contrary to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have not considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this Citigroup earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>